Natco's marketing partner gets USFDA nod for cancer treatment drug

"Breckenridge Pharmaceutical Inc (BPI) has received final approval for its abbreviated new drug application (ANDA) for Everolimus tablets from the US Food and Drug Administration (USFDA)," Natco Pharma said in a regulatory filing.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/3bm3Krv
via IFTTT